Introduction
Interleukin-12 is a heterodimeric soluble cytokine, which has shown antitumor activity in murine tumor models 1, 2 due to its ability to promote cellular immune responses 1, 3 and to impair tumor vascularization. 4, 5 IL-12 mediates its functions through a receptor characterized on T cells and NK cells, 2 but recent functional evidence also shows effects of IL-12 on dendritic cells and macrophages. [6] [7] [8] Classical IL-12R consists of two chains (IL-12R␤1 and IL-12R␤2) which upon stimulation trigger several biochemical signals with activation of Jak-2, Tyk-2 and subsequent phosphorylation, dimerization and nuclear translocation of the transcription factor Stat-4. 2 Recently, an alternative isoform of IL-12R␤2 has been identified on dendritic cells which activates NF-B nuclear translocation. 6 IL-12 has been shown to trigger IFN␥ release not only from T cells and NK cells, 9 but also from macrophages and dendritic cells. 7, 8 Both administration of recombinant protein and IL-12 gene transfer approaches with various vectors have successfully eradicated experimental malignancies. [10] [11] [12] [13] [14] Such encouraging preclinical data prompted testing clinical safety in a number of cancer patients. After a phase I clinical trial that established a maximal tolerated dose of adenovirus coding for reporter genes. In accordance, IL-12 serum concentrations are higher in susceptible mice. In addition, sera from C57BL/6 mice treated with AdCMVmIL-12 showed higher levels of IL-18, a well-known IFN␥ inducer. Interestingly, lethal toxicity in C57BL/6 mice was abolished by administration of blocking anti-IFN␥ mAbs and also by simultaneous depletion of T cells, NK cells, and macrophages. These observations together with the great dispersion of IFN␥ produced by human PBMCs upon in vitro stimulation with IL-12, or infection with recombinant adenovirus encoding IL-12, suggest that patients might also show heterogeneous degrees of toxicity in response to IL-12 gene transfer. Gene Therapy (2001) 8, 259-267. 500 ng/kg for i.v. injection of rhIL-12 in an intra-patient escalation fashion, a phase II trial was started and eventually stopped because of unacceptable toxicity leading to two fatalities. 15, 16 Careful reassessment of patient data and studies in mouse models led investigators to the conclusion that previous low doses of IL-12 in the intrapatient escalation had desensitized the patients to the toxic effects of subsequent doses of IL-12.
17 Most IL-12 toxicity is related to the production of IFN␥, which in turn activates the overproduction of an array of downstream inflammatory mediators. 18, 19 The IL-12 toxicity profile in humans frequently involved leukocytopenia and thrombocytopenia with lower gastrointestinal bleeding and signs of liver dysfunction in some cases. 15, 17, 20 Mice overdosed with IL-12 show alteration in blood counts, extramedullary hematopoiesis, skeletal and cardiac muscle necrosis, wasting, splenomegalia and foci of hepatic necrosis. 15, 17, 18, 20 Lung edema, pleural and peritoneal effusions were also noted. All these effects correlated with IFN␥ serum concentrations and all symptoms but the pulmonary edema were absent in IFN␥ receptor −/− mice, indicating a key role for this soluble mediator. 20 Indeed, anti-IFN␥ blocking mAbs abrogated toxicity in C3H mice overdosed with IL-12.
17 IL-18 has been identified as a potent cofactor of IL-12 to induce IFN␥. 21, 22 IL-12 is instrumental in inducing T H 1 immune responses, enhancing the differentiation of T H 0 naive precursors to produce IFN␥. 2, 23 It has been repeatedly observed that certain mouse strains such as BALB/c are prone to mount T H 2 responses in contrast to others such as C57BL/6 which tend to respond with T H 1-biased responses. This difference accounts for a dramatically distinct outcome upon infection with a number of intracellular parasites. 24 When studying the toxicity of a recombinant adenovirus encoding murine IL-12 (AdCMVmIL-12), we noted that certain mouse strains such as C57BL/6 and DBA/2 were killed by doses of adenovirus which left BALB/c mice largely unaffected. It was found that toxicity correlated with the serum levels of IFN␥. Remarkably different levels of gene transduction in the liver among murine pure strains were observed using reporter genes, offering an explanation for the differences in serum IL-12 and IFN␥. IL-12-induced toxicity, which was completely inhibited by neutralizing anti-IFN␥ mAb, was dependent on T cells, NK cells, and macrophages. In accordance, parallel genetic or epigenetic variability in humans could cause idiosyncratic adverse effects in response to IL-12 gene therapy.
Results
Differential susceptibility to similar levels of systemic IL-12 gene transfer in distinct murine strains Back-crosses of mice have standardized the genetic backgrounds of the inbred strains that are routinely used in the laboratory in order to avoid experimental variability attributable to genetic differences. Such mice are therefore homozygous for the possible alleles in most loci and display phenotypic characteristics that clearly differentiate them from other pure strains. It was observed that 5 × 10 9 p.f.u. i.v of AdCMVmIL-12 killed all C57BL/6 mice, but only two out of five BALB/c mice ( Figure 1a) . One half of this dose (2.5 × 10 9 p.f.u.), again killed all C57BL/6 whereas BALB/c mice were largely unaffected (Figure 1b) . Such a dramatically different outcome was also observed with 10 9 p.f.u. (data not shown). AdCMVmIL-12-injected C57BL/6 mice appeared ill from day 3 after AdCMVmIL-12 injection. They stopped moving in the cages, displayed unattended fur and ate poorly. At day 4, most animals were critically ill with different degrees of respiratory distress. Such mice had leukopenia, thrombocytopenia and showed elevated serum transaminases (data not shown). No signs of obvious gastrointestinal bleeding were found and death occurred presumably in most cases due to respiratory failure. A control adenovirus encoding for ␤-galactosidase (AdCMVLacZ) did not affect either BALB/c or C57BL/6 mice at the same doses or higher doses at least up to 10 10 p.f.u. (data not shown). In contrast, 2.5 × 10 8 p.f.u. of AdCMVIL-12 i.v. killed three out of five C57BL/6 mice and dose dependence was further confirmed since 2.5 × 10 7 p.f.u. failed to kill any of 10 thus treated C57BL/6 mice. Serum levels of IFN␥ were about three times higher in C57BL/6 mice than in BALB/c mice on days 3 and 5 after i.v treatment with AdCMVIL-12 at 2.5 × 10 9 p.f.u. (Figure 1c) . Interestingly, when 2 × 10 6 spleen cells/ml were cultured in vitro 3 days after AdCMVmIL-12 administration, C57BL/6 splenocytes released into the culture supernatants twice as much IFN␥ as BALB/c spleen cells (Figure 1d ). However, no significant differences in the amount of IFN␥ produced by splenocytes from untreated mice of each strain upon in vitro stimulation with recombinant IL-12 could be observed.
In necropsies of moribund C57BL/6 mice upon treatment with 2.5 × 10 9 p.f.u. of AdCMVmIL-12, the liver appeared pale and also slightly enlarged. No signs of hemorrhage within the peritoneal cavity or intestinal tract were noticed. Lungs appeared clearly congestive. Microscopic examination of H&E-stained tissue sections from lung, liver and spleen from identically treated C57BL/6 and BALB/c disclosed a clear disparity in the severity of lesions (Figure 2 ). Livers from C57BL/6 mice showed a focal necrosis with an intense inflammatory infiltrate that correlated with increases in serum ALT and bilirubin (data not shown). C57BL/6 lungs showed an intense leukocyte infiltration and signs of exudate. Spleens showed profound disruption of tissue structure and signs of lymphocyte depletion as previously reported. 25 These lesions were in clear contrast to the milder pathological changes observed in BALB/c ( Figure 2 ).
Heterogeneous levels of liver transgene expression after i.v. injection of recombinant adenovirus
In order to discover reasons for the heterogeneity observed, we looked at the level of expression of ␤-galactosidase in the liver of C57BL/6 and BALB/c mice i.v.-injected with 2.5 × 10 9 p.f.u. of AdCMVLacZ. X-gal histochemical staining data clearly showed that more cells expressed the transgene in C57BL/6 livers and suggested that the intensity of expression on per cell basis was also higher than in BALB/c livers (Figure 3a and b). These data were confirmed when using a similar adenovirus encoding for the enzyme luciferase (AdCMVLuc) and using chemoluminescence in liver homogenates as a read out. As shown in Figure 3c , levels of transgene expression were 10-to 100-fold higher in C57BL/6 livers than in BALB/c ones. Chemoluminescence was almost undetectable in homogenates from spleen and lungs underscoring the liver tropism of adenoviral vectors. When sera from C57BL/6 mice treated with AdCMVIL-12 were compared with sera from identically treated BALB/c mice for the content of IL-12, we also detected higher levels in C57BL/6, again consistent with a higher level of gene transduction in this strain ( Figure 3d ). It is noteworthy that differences in gene transduction between strains with reporter genes are greater than those measured with IL-12 serum concentrations, indicating the existence of distinct regulatory mechanisms, in spite of the fact that both genes are under the control of the same promoter.
A panel of mouse strains show variability in AdCMVmIL-12-induced toxicity Apart from the remarkable contrast in the survival outcome of C57BL/6 mice and BALB/c mice, we analyzed the effect of 2.5 × 10 9 p.f.u. of AdCMVmIL-12 in other genetic backgrounds to look for variability.
The F1 (C57BL/6 × BALB/c) mice were not killed and remained largely unaffected by AdCMVIL-12 ( Figure 4a with samples from identically treated BALB/c and C57BL/6 (not shown). In DBA/2, i.v. AdCMVmIL-12 induced toxicity that was as severe as in C57BL/6 mice. In this case, such mice have a H2 haplotype (H2 d ) identical to that present in the BALB/c genome suggesting that the character susceptibility/lack of susceptibility to AdCMVmIL-12 is unrelated to this locus. B10.D2 mice also bearing H2 d showed intermediate levels of toxicity with approximately 40% lethality (three out of seven) and a delay of several days in the gap from AdCMVmIL-12 injection to death in comparison with C57BL/6 and DBA/2 ( Figure  4a ).
u. (b). Survival was monitored daily thereafter. (c) Blood samples were drawn from the orbital plexus on days 3 and 5 after AdCMVmIL-12 i.v. injection. IFN␥ concentrations were assessed by ELISA and individual data of a representative experiment out of four performed are shown (statistical comparision was by Mann-Whitney test). (d) IFN␥ concentration (mean
Serum IFN␥ concentrations in DBA/2 mice at day 3 after AdCMVmIL-12 injection were found to reach higher levels than in identically treated BALB/c, but lower than in C57BL/6 mice ( Figure 4b ). Such data suggest that different genetic backgrounds could determine adverse effects for IL-12 gene therapy. However, differences in IFN␥ serum concentrations between B10.D2 and BALB/c were not found in spite of the different survival outcomes.
Neutralization of IFN␥ prevents AdCMVmIL-12 lethal toxicity as well as simultaneous depletion of CD4 + , CD8 + , NK cells and macrophages Systemic administration of a lethal dose of AdCMVmIL-12 to C57BL/6 mice was associated with high IFN␥ proGene Therapy duction. Repeated i.p. injection of a blocking anti-murine IFN␥ mAb protected all mice and resulted in the same survival as that of identically treated BALB/c mice. Accordingly, IFN␥ is critically involved in mechanisms determining toxicity.
IFN␥ is mainly secreted by T and NK cells. To study the role of such cell populations in the lethal effect observed on C57BL/6 mice, we depleted CD4 + , CD8 + and NK cells both separately or in combination ( Figure 5 ) with specific antibodies. Although such depletions were complete upon FACS analysis of peripheral blood mononuclear cells (data not shown), mice succumbed to AdCMVmIL-12 albeit with some delay if compared with control mice.
In contrast, depletion of NK cells, CD4 + , and CD8 + cells plus treatment with macrophage-depleting doses of gadolinium chloride 26 fully protected AdCMVmIL-12-treated C57BL/6 mice from death. Gadolinium treatment by itself did not protect mice indicating that only simultaneous elimination of all such cell populations (T, NK and macrophages) was protective ( Figure 5 ).
Besides the differential gene transduction levels of IL-12, we looked for other reasons that could be enhancing the output of IFN␥. IL-18 levels were twice as high in the sera of C57BL/6 mice treated with AdCMVIL-12 than in equally treated BALB/c 5 days after adenovirus administration ( Figure 6 ). When AdCMVLacZ was used as a control, no IL-18 levels in sera were detected (not shown). Since IL-18 is a cofactor for IFN␥ production known to contribute in enhancing IL-12 toxicity, 21, 22 we speculated that neutralization of IL-18 with specific antibodies would ameliorate toxicity of AdCMVIL-12 in C57BL/6 mice. However, no delay in the onset of symptoms or death time-points was observed in spite of the fact that IL-18 was not detectable in the serum of such animals.
Human subjects show diversity in the IL-12-induced level of secretion of IFN␥ from peripheral blood mononuclear cells In order to investigate whether human subjects quantitatively differed in the capability of their PBMCs to respond to IL-12 in terms of in vitro IFN␥ production, a sample of healthy volunteers (n = 22) was chosen. PBMCs purified over Ficoll gradients were exposed to 10 ng/ml of rhIL-12, and IFN␥ concentrations released into the supernatants were determined by ELISA. A great dispersion was found in the production of IFN␥ (CV = 90%) with a range from 150 pg/ml to 13 000 pg/ml (Figure 7a) . We could not assess the level of infection by adenovirus in human liver cells from different subjects but our data suggest that other features could account for differential susceptibility to IL-12-mediated adverse effects in humans. We also infected in vitro PBMCs of 16 donors with an adenovirus encoding human IL-12 (AdCMVhIL-12) and again great dispersion was observed in the output of IFN␥ into the supernatants (Figure 7b ). Variability of infection on per cell basis was difficult to assess since recombinant adenovirus only infected a small proportion (less than 5%) of PBMC, mainly among the adherent population. A good correlation was found in the level of IFN␥ induced by rIL-12 and AdCMVhIL-12, indicating that the main factor of variability in humans was the response to IL-12. It should be noted that PBMC secreted detectable levels of IFN␥ in six of 12 cases also in response to AdCMVLacZ (not shown), probably reflecting previous contact of the subjects with adenoviral antigens, thus adding another potential factor for individual variability.
As a whole these data suggest that several factors could account for individual variability among humans in IFN␥ production in response to IL-12 gene therapy, giving rise to a spectrum of differential toxicity.
Discussion
In this study we describe differential susceptibility to systemic gene transfer of IL-12 in various mouse strains which can be accounted for by quantitative variations in IFN␥ production. At least for C57BL/6 and BALB/c, the difference seems to be related to a differential level of gene transduction in liver cells by identical doses of first generation recombinant adenovirus. Reasons for differential level of transduction could involve several steps in the process, from viral entry to gene expression. No difference in surface MHC class I or ␣ v ␤ 3 were found by flow cytometry on the surface of hepatocyte cell suspensions from C57BL/6 and BALB/c. These proteins are known to be involved in virus attachment and internalization. 27 We are trying to explore a possible differential expression of CAR (Coxackie adenovirus receptor) but no reliable mAbs against mouse CAR are yet available. It should be stressed that differential gene transduction might not be the only mechanism involved in differential susceptibility, and accordingly, we detect more intense differences in transduction levels of luciferase than in serum levels of IL-12 suggesting that compensatory mechanisms have been elicited in the case of IL-12.
Data with gene transduction of luciferase in F1 (BALB/C × C57BL/6) livers show that gene transduction levels are intermediate to those in the parental strains. The genetic trait for this character is currently being explored with analysis of the F2 generation attempting to find the gene or genes involved. Interestingly, IFN␥ in sera from F1 mice treated with AdCMVIL-12 is similar to that in sera from BALB/c, again indicating that other mechanisms of regulation beyond gene transduction exist in the case of the cytokines.
IL-12 has proved to be a major hope in the fight against cancer. 1 Both treatment with purified protein and gene transfer with recombinant vectors have displayed unprecedented success in murine experimental tumors. Recent data in cutaneous lymphoma patients undergoing systemic or intralesional injection of rhIL-12 have also been extremely encouraging. 28 Our group as well as others is about to start clinical trials in cancer patients based on intratumoral injection of IL-12 encoding adenoviruses. Although confinement of IL-12 to the lesion should clearly downsize the systemic adverse effects, there is much interest in the assessment of potential risks and adverse reactions.
u. of AdCMVLacZ (×100). (c) Relative light units per g of total protein in liver homogenates from BALB/c and C57BL/6 mice treated with two doses of AdCMVLuc. Data represent individual mice from a representative experiment. Statistical comparison was by Mann-Whitney test. (d) IL-12 serum concentrations in sera of C57BL/6 o BALB/c mice 3 days after i.v. injection of AdCMVIL-12 (statistical comparison was by Mann-Whitney test).
Previous differential toxicity to IL-12 among mouse strains has been found in a model of glomerulonephritis and genetic background-related differences in the spectrum of IL-12-induced lesions had been noted previously. 29 We report a dramatic difference in survival over a wide range of doses. Importantly, we have found that in vivo depletion of CD4 + , CD8 + asialoGM-1 + and
Gene Therapy gadolinium-sensitive cells was required to achieve the same level of protection as that observed when blocking with anti-IFN␥ antibodies. Both CD4 and CD8 T cells and NK cells are known to be major sources of IFN␥. In fact, a crucial role of NK cells in a toxic shock model induced by combined administration of IL-2 and IL-12 has been demonstrated. 30 Curiously, IFN␥ was not neccessary in that system since toxicity occurred in IFN␥ receptor −/− mice. 30 The role of macrophages shown in mice treated with gadolinium is difficult to assess. On one hand, they are potential sources of IFN␥ as recently reported, 7 and on the other hand, they can secrete many downstream inflammatory mediators in response to IFN␥. 31 Recent information also suggests a major role for lymphoid dendritic cells as a source of IFN␥. 8 It should be noted that depletions with anti-CD8␣ mAbs also deplete a subset of this cell type. 8 We have found interesting differences in the levels of serum IL-18 among susceptible and non-susceptible mouse strains. IL-18 is a potent promoter of IFN␥ 32 production that synergizes with IL-12 22 but we could not inhibit toxicity with anti-IL-18 neutralizing antibodies. Thus, although IL-18 could be involved in the differential toxicity observed, its role does not appear to be critical.
Although highly expressed in macrophages, iNOS (inducible nitric oxide synthetase) activity is not an absolute requirement for IL-12 toxicity since C57BL/6 mice treated with the NOS inhibitor L-NAME also succumb to IL-12 gene transfer as well as iNOS −/− mice (data not shown). None the less, iNOS activity has been found to be instrumental for the immunosupression observed after overdosing IL-12. 25, 33 We present data that suggest human individual variability in the response to IL-12 gene transfer. Although our data are preliminary, this issue is important when considering clinical development of such adenoviruses. It is of note that our AdCMVhIL-12 has been tested in non-human primates and that serious toxicity was found only after injection of very high systemic doses of the recombinant adenovirus (Sangro et al, manuscript in preparation). Our plans for the clinic only involve intratumoral injection which has shown remarkable efficacy and safety profiles in mouse tumor models probably related, as mentioned above, to confinement of high concentrations of IL-12 to the local tumor environment only. However, it is noteworthy that even under those conditions some viral vector reaches systemic circulation and infects liver cells. 34 Our data with human PBMCs uncover at least two possible sources of polymorphism in the response to IL-12 gene therapy in humans: (1) differential infectability of liver cells likewise among murine strains, (2) variable sensitivity to IL-12 in IFN␥-secreting cells. In vitro laboratory tests assessing IFN␥ secretion from PBMCs in response to rhIL-12 or AdCMVhIL-12 might correlate with different clinical outcomes or adverse reactions. As a whole, our results indicate that individual variability might cause shifts in the dose/response curve for IL-12 gene therapy and such information would be important for clinical development.
Materials and methods

Construction of adenovirus
Recombinant adenovirus carrying murine IL-12 (AdCMVmIL-12) has been previously reported. 35 Briefly, an expression cassette of IL-12 under the control of the CMV promoter was constructed encompassing IL-12 p35 cDNA, an internal ribosomal entry site (IRES), IL-12 p40 cDNA and a polyadenylation signal. Recombinant adenovirus encoding the IL-12 cassette of expression was generated by cotransfection of 293 cells according to standard procedures. 36 Adenovirus carrying lacZ (AdCMVLacZ) or luciferase reporter genes (AdCMVLuc, a kind gift from Dr David Brenner, University of North Carolina, Chapel Hill, NC, USA) under the control of the CMV promoter were produced similarly. Recombinant adenoviruses were isolated from a single plaque, expanded in 293 cells, and purified by double cesium chloride ultracentrifugation. Purified virus was extensively dialyzed against 10 mm Tris 1 mm MgCl 2 and stored in aliquots at −80°C and was carefully titrated by plaque assay. 36 The adenovirus encoding the genes of human IL-12 (AdCMVhIL-12) will be described elsewhere (C Qian et al, manuscript in preparation). ) mice were purchased from Harlan (Barcelona, Spain) and were housed according to institutional guidelines. The 293 cells were maintained in DMEM medium supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mm l-glutamine, 100 U/ml streptomycin, 100 g/ml penicillin. All cell culture reagents were from GIBCO (Basel, Switzerland).
Peripheral blood was obtained from healthy volunteers donors. Fresh peripheral blood mononuclear cells (PBMC) were separated by Ficoll-Hypaque density gradient centrifugation (Vacutainer; Becton Dickinson, Madrid, Spain) and cultured in RPMI 1640 medium with 100 U/ml streptomycin, 100 g/ml penicillin, 10 g/ml ciprofloxacin, and supplemented with 10% FCS. Recombinant hIL-12 and mIL-12 were obtained from Peprotech (London, UK).
Animal studies
Mice in groups of five to seven received a single i.v. injection of AdCMVmIL-12 at different doses on day 0. In some cases mice received i.p. administration of mAbs or i.v. gadolinium chloride. Mice were carefully observed for signs of toxicity and followed daily for survival. In some cases mice receiving AdCMVLuc were killed and their livers removed for generation of tissue homogenates.
Serum levels of IFN␥, IL-12 and IL-18
Mouse and human IFN␥ concentrations (Endogen, Woburn, MA, USA), IL-12 (Pharmingen, San Diego, CA, USA)
Gene Therapy and IL-18 (R&D Systems, Abingdon, UK) were assessed by enzyme-linked immunoabsorbent sandwich assay (ELISA) according to the manufacturer's instructions.
Mouse blood samples were drawn from the retroorbital sinus. Red cell-depleted splenocytes in RPMI 1640 10% FCS for 24 h and tissue culture supernatants were proccessed. Human peripheral mononuclear cells were obtained by Ficoll gradient centrifugation from healthy volunteers.
Luciferase assays on mouse livers
Mice were killed at day 3 after systemic AdLuc administration. Livers were harvested and stored at −80°C. After thawing, 1.5 ml of Reporter Lysis Buffer (Promega, Madison, WI, USA) was added to each liver specimen. Liver tissues were homogenized using Ultraturrax (Ika-Werke, Staufen, Germany) at room temperature, and cell debris was removed by two sequencial high speed centrifugations. Twenty l of cell-free extracts were added to 100 l of luciferase assay reagent (Luciferase Assay System; Promega). Relative light units (RLU) were determined using EG&G Berthold Luminometer (Aliquippa, PA, USA). Total amount of liver protein was determined by the BCA Protein Assay Kit (Pierce, Rockford, IL, USA).
X-gal staining AdCMVLacZ (2.5 × 10 9 p.f.u.) in 150 l of saline was injected intravenously into C57BL/6 and BALB/c mice. Animals were killed 3 days later, and the livers were excised, immediately embedded in optimal cutting tempereture compound (OCT; Tissue Tek, Zoeterwoude, The Netherlands) and frozen in liquid nitrogen. Sections of 6-m thickness were fixed with glutaraldehyde (0.5%) and stained with 5-bromo-4-chloro-3-indolyl-␤-galactosidase as described previously. 37 Depletion of lymphocytes, NK cells and macrophages L3T4 (CD4 + )-specific rat anti-mouse hybridoma GK1-5 and (CD8 + )-specific rat anti-mouse hybridoma H35.17.2 were used to obtain anti-CD4
+ and anti-CD8 + antibodies (ATCC, Rockville, MD, USA). Ascitic fluid was obtained from pristane-primed nude mice injected with 10 6 hybridoma cells. Mice, four to five in each group, were depleted of CD4 + or CD8 + cells by intra-peritoneal injection of 100 l of anti-CD4 + or anti-CD8 + antibodies five times, on days −3, −2, −1, 7 and 14. Animals received an i.v. injection of AdCMVmIL-12 on day 0. Depletion of NK cells was accomplished via i.v. (100 l per dose) administration of a rabbit anti-AsialoGM1 antiserum (Wako, Neuss, Germany) on day −2, −1, before AdCMVmIL-12 administration and every 7 days thereafter. 38 Anti-IFN␥ mAb (R4-6A2; ATCC) was given i.p. as ascitis fluid (100 l per dose) starting on days −2, −1 and every 3 days thereafter. Mice were depleted of monocytes/ macrophages by i.v. injection of 10 g/kg per dose gadolinium chloride (Aldrich, Milwaukee, WI, USA) 36 and 3 h before AdCMVmIL-12 injection and every 2 days thereafter.
Pathological studies Animals were killed 5 days after AdCMVmIL-12 therapy. Liver, spleen and lung were collected, fixed in 10% buffered formalin, sectioned and stained with hematoxylin and eosin (H&E) for histopathological analysis. Blood counts, serum aminotransferases and creatinine were measured by standard clinical laboratory techniques.
